Analysts Set Humana Inc. (NYSE:HUM) PT at $315.86

Humana Inc. (NYSE:HUM) has been given an average rating of “Hold” by the twenty-five ratings firms that are presently covering the stock, MarketBeat.com reports. Nineteen equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $304.15.

HUM has been the subject of several research reports. Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price for the company in a research report on Tuesday, October 8th. Truist Financial lowered their price objective on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a research report on Friday, October 11th. Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Cantor Fitzgerald reissued a “neutral” rating and set a $395.00 price target on shares of Humana in a research report on Tuesday, October 1st. Finally, Stephens restated an “equal weight” rating and issued a $250.00 price objective on shares of Humana in a report on Wednesday, October 9th.

Humana Stock Performance

Shares of HUM stock opened at $274.14 on Wednesday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a fifty day moving average of $273.45 and a 200 day moving average of $325.22. The firm has a market capitalization of $33.01 billion, a price-to-earnings ratio of 24.16, a PEG ratio of 2.15 and a beta of 0.53. Humana has a 52 week low of $213.31 and a 52 week high of $486.00.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. As a group, research analysts expect that Humana will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a yield of 1.29%. Humana’s dividend payout ratio is currently 31.36%.

Institutional Trading of Humana

Several hedge funds have recently bought and sold shares of HUM. Creative Financial Designs Inc. ADV lifted its position in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares in the last quarter. CarsonAllaria Wealth Management Ltd. lifted its holdings in Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares in the last quarter. Atwood & Palmer Inc. bought a new position in shares of Humana in the third quarter worth approximately $29,000. Ashton Thomas Securities LLC purchased a new stake in shares of Humana in the third quarter worth $31,000. Finally, Your Advocates Ltd. LLP increased its stake in shares of Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.